Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus radiotherapy for metastatic recurrent prostate cancer without androgen deprivation
ACTRN12619000097145Phase 2Completed
- Sponsor
- Northern Sydney Local Health District
- Start
- Feb 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in prostate cancer (PCa), sponsored by Northern Sydney Local Health District. Primary endpoints: PSA progression-free survival and Toxicity. Started Feb 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12619000097145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000097145.